Not getting enough sleep does more than make you tired. Here’s how short nights can quietly raise your blood pressure, and ...

The first evidence of the existence of renin was presented by Tigerstedt over 100 years ago. However, the importance of renin and the renin–angiotensin system (RAS) in the pathogenesis of ...

Finerenone shows significant benefits in patients with kidney disease and type 1 diabetes, which could lead to the first ...

AstraZeneca and Sun Pharma will jointly market SZC, a key hyperkalaemia drug for CKD and heart failure patients, under ...

In A Nutshell • A pig kidney with just one genetic modification functioned in a human for 61 days before being removed as ...

CKD prevalence has more than doubled since 1990, with 788 million adults affected in 2023, highlighting a significant global health challenge. The disease is a major contributor to cardiovascular ...

A real-world analysis published in JACC Advances concludes that heart failure patients prescribed ivabradine face a significantly higher risk of developing atrial fibrillation (AF) within 180 ...

Rising chronic kidney disease prevalence and morbidity rates in 2023 make CKD the ninth leading cause of death globally, ...

Balcinrenone is similar to finerenone (Kerendia), which is also a nonsteroidal MRA and was approved for the slowing of ...

Adverse changes in the heart’s structure and function are common in people with chronic kidney disease (CKD), warranting mitigating therapies.

AstraZeneca will market the therapy as Lokelma, while Sun Pharma will promote and distribute it as Gimliand. AstraZeneca will ...

AstraZeneca Pharma and Sun Pharma have announced an exclusive partnership to promote and distribute SZC for hyperkalaemia treatment under separate brands, aiming to expand patient access across India ...